Perspective Therapeutics Advances [212Pb]VMT01 Monotherapy in Metastatic Melanoma Trial

Perspective Therapeutics, Inc. (NYSE American: CATX), a radiopharmaceutical company focused on pioneering new cancer treatments, announced that the first patient has been dosed in a newly opened cohort of its ongoing Phase 1/2a clinical trial. The study is evaluating [212Pb]VMT01, a targeted alpha-particle therapy (TAT), as a monotherapy in patients with melanoma who have tested positive for the melanocortin 1 receptor (MC1R) on imaging scans.

In this cohort, patients are receiving a 1.5 mCi dose of [212Pb]VMT01 as a standalone therapy. This stage of the trial builds on earlier promising results presented at the Society for Melanoma Research Congress in October 2024. The study also includes a separate cohort launched in March 2025 that is exploring [212Pb]VMT01 in combination with the immune checkpoint inhibitor nivolumab.

“This next step in evaluating [212Pb]VMT01 as a monotherapy is particularly important, as it includes patients whose melanoma has spread to the brain—a common and challenging form of metastasis,” said Dr. Markus Puhlmann, Chief Medical Officer at Perspective. “Imaging studies using [203Pb]VMT01 and [68Ga]VMT02 have previously shown uptake in brain metastases, supporting the rationale for including these patients in our study.”

Thijs Spoor, CEO of Perspective, added, “By studying VMT01 both on its own and in combination with immunotherapy, we aim to accelerate our understanding of how best to deploy this therapy in real-world treatment settings. We believe this dual approach will help us move more quickly toward delivering a new treatment option to patients facing metastatic melanoma.”